IL10 and cancer: Intriguingly, we found that treatment of PBMCs with WNK463 significantly enhanced the production of immune-activating cytokines, including IFN-γ and TNF-α, but suppressed immunosuppressive cytokines, such as IL-10, at a concentration that did not affect the viability of PBMCs (Fig. 2c), suggesting the dual antitumor mechanisms of WNK463 for PD-L1 suppression on cancer cells together with immune cell activation.